Revanesse

Treatment areas

 

Product Outline

Production process

Thixofic cross-linking technology

Because there are many Hyaluronic acid based fillers on the market, one may ask: “What makes the Revanesse product line different?”

The answer lies in our unique formula and patented Thixotropic cross-linking technology, which allows
a highly viscous gel to be injected easily through a fine gauge needle without causing degradation to the modified Hyaluronic acid particles.

Prollenium’s precisely crafted cross-linking process is designed to maximize the effectiveness of the cross-linked chains present in the gel. This leads to a gel, which derives maximum benefit in terms of mechanical properties and durability, with a minimum amount of BDDE.

The osmolality and pH of the gel is balanced to be compatible with the fluid in the skin, neither drawing in or releasing water. This minimizes problems of overfilling or the need for volume correction. The degree of cross-linking is also selected to provide a desirable level of durability in the skin.

Optimizing all these properties provides for a dermal filler with superior performance and patient satisfaction.

Ease of use

The greatest care has been taken to ensure that the Revanesse line of fillers are easy to inject. The syringe has been designed to include extra-wide finger flanges and broadened pistons that provide much greater ease of use. This design allows the practitioner a much higher degree of flexibility when injecting.

Safe & effective

The Hyaluronic acid used in our products is obtained through biosynthesis, making it safe and non-pathogenic for humans. With less than 0.025 IU/mg of endotoxins and less that 2 ppm of protein*, it exceeds the highest standard of purity for HA.

Revanesse is completely free of all animal products, thus reducing the risk of an immunogenic reaction. The Hyaluronic acid is naturally integrated into the tissue keeping the skin looking healthy and natural.

Safety is our utmost concern.

The following tests have been conducted:

  • 4 weeks muscle implantation
  • Acute systemic injection test
  • Biocompatibility text
  • Cytotoxicity
  • Identification: pH, osmoality, residual BDDE, sterility
  • Intracutaneous reactivity
  • Mutagenicity
  • Protein
  • Reverse mutation assay
  • Tests for interactions with blood haemolysis test
  • Tests for local effect after implantation
  • Acute toxicity
  • Subchronic toxicity
  • 26 weeks biocompatibility and toxicity study

*Testing by AppTec Inc., Pennsylvania, USA

Comparison

Stabilised
Hyaluronic acid

Other Ingredients

Source

Syringe Size

Revanesse

25mg/ml

Non-animal

1.0ml

Revanesse Ultra

25mg/ml

Non-animal

1.0ml

ReDexis

25mg/ml

25mg Sephadex

Non-animal

1.0ml

ReDexis Ultra

17mg/ml

50mg Sephadex

Non-animal

1.0ml

Juvederm Ultra / Plus

24mg/ml

Non-animal

0.8ml

Restylane

20mg/ml

Non-animal

1.0ml

Perlane

20mg/ml

Non-animal

1.0ml

Radiesse

CaHa

Non-animal

1.3ml

Juvederm is a registered trademark of Allergan Inc.
Restylane Touch and Perlane are registered trademarks of HA North American Sales.
Radiesse is a registered trademark of Bioform Medical Inc.